AZ, Daiichi's Enhertu cleared by FDA in wide range of tumors
WEBApr 8, 2024 · The latest nod marks Enhertu’s fifth approved indication in the U.S. The ADC, which won its original nod in 2019, is also cleared to treat HER2-positive and HER2-low breast cancer, plus gastric...
Enhertu demonstrated a median progression-free survival of 13.2 …
WEBJun 2, 2024 · With Enhertu (trastuzumab deruxtecan), a HER2-directed antibody drug conjugate (ADC), AstraZeneca and Daiichi Sankyo are aiming to improve outcomes in previously treated HER2-positive and HER2-low metastatic breast cancer and are exploring its potential in earlier lines of treatment and in new breast cancer settings.
Enhertu Approved for Any HER2-Positive Solid Cancer - NCI
WEBMay 3, 2024 · The drug trastuzumab deruxtecan (Enhertu) can now be used to treat a wide variety of cancers, thanks to a new approval from the Food and Drug Administration (FDA).
Enhertu demonstrated clinically meaningful survival across …
WEBOct 23, 2023 · AstraZeneca and Daiichi Sankyo’s Enhertu showed a median progression-free survival of 6.9 months and median overall survival of 13.4 months in the overall trial population
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the …
WEBApr 5, 2024 · AstraZeneca and Daiichi Sankyo's ENHERTU ® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.
Enhertu Dramatically More Effective Than Kadcyla as Second …
WEBEnhertu more than doubled the 12-month progression-free survival rate than Kadcyla in people with metastatic HER2-positive breast cancer that had been treated.
Enhertu demonstrated statistically significant and clinically ...
WEBApr 29, 2024 · With Enhertu (trastuzumab deruxtecan), a HER2-directed antibody drug conjugate (ADC), AstraZeneca and Daiichi Sankyo are aiming to improve outcomes in previously treated HER2-positive and HER2-low metastatic breast cancer and are exploring its potential in earlier lines of treatment and in new breast cancer settings.
Enhertu Effective in HER2-Positive Metastatic Breast Cancer
WEBOct 19, 2021 · In people with metastatic HER2-positive breast cancer, the targeted drug trastuzumab deruxtecan (Enhertu) markedly lengthened progression-free survival compared with trastuzumab emtansine (Kadcycla), new study results show.
AstraZeneca's Enhertu sBLA Gets FDA Priority Tag for Expanded Use
WEBOct 1, 2024 · The FDA grants priority review to AZN's sBLA for Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer. A decision is due in first-quarter 2025. News
ENHERTU® Granted Priority Review in the U.S. for Patients with ...
WEBJan 29, 2024 · Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/Nasdaq: AZN) supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been accepted and granted Priority Review in the U.S. for the treatment of adult patients with unresectable or metastatic HER2 positive …